MELBOURNE, Australia and SAN FRANCISCO, Jan. 30, 2025 (GLOBE NEWSWIRE) -- Alterity Therapeutics (ASX: ATH, NASDAQ: ATHE) (“Alterity” or “the Company”), a biotechnology company dedicated to developing ...

Multiple system atrophy and Parkinson’s disease are progressive nervous system disorders that affect everyday movements. Multiple system atrophy is rarer and tends to progress more quickly. Multiple ...

Currently no disease-modifying or neuroprotective treatments exist for MSA, nor are there effective medications to treat the cerebellar ataxia in MSA-C or the parkinsonian features in MSA-P. Physical ...

MELBOURNE, Australia and SAN FRANCISCO, April 10, 2025 (GLOBE NEWSWIRE) -- Alterity Therapeutics (ASX: ATH, NASDAQ: ATHE) (“Alterity” or “the Company”), a biotechnology company dedicated to developing ...

Aussie biotech Alterity Therapeutics Ltd. released interim data of an open-label phase II trial for lead candidate ATH-434 for treating multiple system atrophy that showed 43% of participants improved ...

Alterity Therapeutics Limited (NASDAQ:ATHE) is among the 12 Best Australian Stocks to Buy Right Now. The company recently reported positive topline data from an open-label Phase 2 clinical trial of ...

HONOLULU — A novel “moderate-affinity iron chaperone” known as ATH434 (Alterity Therapeutics) may slow disease progression in patients with multiple system atrophy (MSA), new research suggested. The ...

An experimental drug that Theravance Biopharma touted as a potential first-in-class medicine for multiple system atrophy has failed a Phase 3 study, triggering a corporate shakeup that ends this ...